Could Weight Loss Drugs Also Be Longevity Drugs? Here's What New Research Found Researchers are exploring whether medications like Ozempic and Zepbound, originally developed for weight loss and diabetes management, might also have the potential to extend lifespan. Early studies suggest a possible link between these drugs and slowed biological aging, though experts caution that the evidence remains preliminary. The New York Times reported that a recent trial involving people with HIV who took semaglutide—the active ingredient in Ozempic—showed signs of slower aging based on blood biomarkers. The study, led by Michael Corley, PhD, of the University of California, San Diego’s Stein Institute for Research on Aging, raised questions about whether the drug could have broader implications for longevity. Corley noted that the findings provided a “signal” worth investigating, though he emphasized that the results do not yet confirm a direct connection to extended lifespan. The potential of GLP-1 drugs, the class of medications that includes Ozempic and Zepbound, lies in their ability to improve metabolic health, lower blood sugar, and reduce risks for conditions like heart disease and diabetes—two of the leading causes of mortality. Nicolas Musi, MD, director of the Diabetes and Aging Center at Cedars-Sinai, told The New York Times that because these drugs address age-related diseases, it is reasonable to consider their role in promoting longevity. Scientists believe GLP-1 drugs may influence biological pathways tied to aging, such as reducing chronic inflammation, which is linked to accelerated aging and age-related illnesses. However, the connection between these mechanisms and actual lifespan extension remains unproven.#new_york_times #glp_1_drugs #michael_corley #university_of_california_san_diego #cedars_sina
